Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Maia Biotechnology Q3 2026 Results: Net Loss of $7.18M, Loss Narrows

For the nine months ended September 30, 2026, MAIA Biotechnology reported a net loss of $21.5 million, driven by $23.3 million in operating expenses. The company significantly strengthened its cash position to $21.3 million, up from $8.7 million at year-end 2025, primarily through a public offering that raised approximately $31.0 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-7.2-8.9
EPS (diluted, $ a share)$-0.12$-0.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: MAIA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Maia Biotechnology, Inc.: key numbers

Share price
$1.25Close, Nov 17
Market cap
$77.2M
Shares outstanding
61.75MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Maia Biotechnology, Inc.

All →
4:07 PM ET Form 4
Insider Buying

Maia Biotechnology Insider Stan Smith Buys $100K of Stock

Stan Smith bought 100,000 shares of Maia Biotechnology, Inc. at $1.00 a share, worth $100K in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 1,619,178 (+1.2%).

Value
$100K
Shares
100,000
Average price
$1.00
Holding change
+1.2%
Trade date
Nov 13, 2026 to Nov 16, 2026
4:06 PM ET Form 4
Insider Buying

Maia Biotechnology CEO Vlad Vitoc Buys $100K of Stock

Vlad Vitoc, CEO, bought 100,000 shares of Maia Biotechnology, Inc. at $1.00 a share, worth $100K in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 1,149,121 (+3.6%).

Value
$100K
Shares
100,000
Average price
$1.00
Role
CEO
Holding change
+3.6%
Trade date
Nov 13, 2026 to Nov 16, 2026
9:01 AM ET 8-K
Clinical Trial Data

Maia Biotechnology Clinical Trial Data

MAIA Biotechnology reported updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine (THIO) in patients with advanced non-small cell lung cancer (NSCLC). The trial demonstrated an 88% disease control rate (DCR) in third-line patients who had progressed after prior immunotherapy and chemotherapy, significantly higher than the 25-35% DCR typically seen with standard chemotherapy.

8:16 AM ET 8-K
Investor Presentation

Maia Biotechnology Investor Presentation

MAIA Biotechnology, Inc. has prepared and posted a new corporate investor presentation and a summary highlighting its operations and performance to its website. Management intends to use these materials for upcoming presentations to investors and analysts starting October 6, 2026.

9:04 AM ET Form 4
Insider Buying

Maia Biotechnology Insider Ramiro Guerrero Buys $49.5K of Stock

Ramiro Guerrero bought 37,595 shares of Maia Biotechnology, Inc. at $1.32 a share, worth $49.5K in total on Sep 10, 2026. Shares held after the trade: 773,296 (+5.1%).

Value
$49.5K
Shares
37,595
Price
$1.32
Holding change
+5.1%
Trade date
Sep 10, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.